SOLICITATION NOTICE
B -- Exome Sequencing of 50 DNA Samples
- Notice Date
- 6/11/2014
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NIH-HHS-NHLBI-CSB-(HG)-2014-151-DLM
- Archive Date
- 7/2/2014
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: The National Institute of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Macrogen Corporation, 9700 Great Seneca Highway, Suite 208, Rockville, Maryland 20850 to procure the following for NHGRI Undiagnosed Disease Program (UDP): Procurement : This is a Follow-On Requirement. 1. Exome Sequencing of 50 DNA Sample. (Samples to be sequenced to at least 50 - fold(50X) average on target depth coverage) BACKGROUND: The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency conducting and supporting medical discoveries that improve people's health and save lives. The National Human Genome Research Institute (NHGRI), NHGRI supports the development of resources and technology that will accelerate genome research and its application to human health. A critical part of the NHGRI mission continues to be the study of the ethical, legal and social implications (ELSI) of genome research. NHGRI also supports the training of investigators and the dissemination of genome information to the public and to health professionals. NHGRI launched a new strategic plan, "Charting a course for genomic medicine from base pairs to bedside", articulating a new vision for the future of genomics research and describing the path towards an era of genomic medicine. The National Human Genome Research Institute (NHGRI), National Institutes of Health Undiagnosed Disease Program (UDP) mission include finding accurate diagnoses and discovering new diseases that provide insight into human physiology and genetics. The UDP was established to evaluate participants who have undiagnosed medical conditions. UDP participants have generally received extensive diagnostic workups before traveling to the NIH and often have numerous and/or complex medical problems. The UDP program makes use of a diverse set of diagnostic and research techniques both to attempt to find a diagnosis and to generate research projects to advance medical knowledge. Objectives: The NIH UDP uses an innovative paradigm for selecting patients (based upon potential for representing a new disease), for phenotyping (extensive multidisciplinary investigations at no cost to the patient), performing genetic studies (combined SNP and WES analysis using family members and filtering programs developed in house). Specific areas of interest include techniques for studying dominant inheritance and identifying families that are most likely to generate verifiable sequence variants as a result of NGS applied as an agnostic, diagnostic screen for genetic disease. Sequence variants identified by NGS are verified by Sanger sequencing following PCR amplification of the regions predicted by NGS to contain said variants. Based on the reagent, maintenance and personnel costs for in house sequencing, the UDP laboratory contracts out the Sanger sequencing of said PCR products to achieve economies of scale and maintain high quality results. Period of Performance: 6-8 Weeks upon Award JUSTIFICATION : Macrogen Corporation has been providing sequencing service for the Undiagnosed Diseases Laboratory for the past two years. Macrogen offers same day free pick up from the laboratory, a 24-hour turnaround time for results, and high quality data return. It is necessary for the Undiagnosed Disease Laboratory to retain the sequencing service provided by Macrogen in order to maintain experimental consistency and to avoid delays incurred by re-optimization of experimental design, bioinformatics testing and redesign, and restructuring the laboratory database that is already in use. The quality of the responsiveness and quality of the service that Macrogen continues to provide to NHGRI/UDP continues to be excellent. Macrogen enrichment will be performed using Agilent's SureSelectXT all Exon v5 Exome enrichment kits (post capture). Sequencing will be performed using the latest Illumina HiSeq 2000 and 2500 systems; and software with 100-bp paired-end sequencing method. REGULATORY AUTHORITY: This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source, only one responsible source and no other supplies or services will satisfy agency requirements. ADDITIONAL INFORMATION: Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology, with a business size standard of 500. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-74 (May 30, 2014). This requirement is under the SAT of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by June 17, 2014 and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2014-151-DLM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NIH-HHS-NHLBI-CSB-(HG)-2014-151-DLM/listing.html)
- Place of Performance
- Address: Vendors and Government Location, United States
- Record
- SN03392717-W 20140613/140611235822-a6043a99f47f279c227e053109312740 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |